Drug Profile
NP G2 044
Alternative Names: NP-G2-044Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Novita Pharmaceuticals; Weill Cornell Medical College
- Developer Novita Pharmaceuticals
- Class Amides; Antineoplastics; Fluorinated hydrocarbons; Furans; Indazoles; Small molecules
- Mechanism of Action Fascin protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
- 26 Oct 2022 Pharmacodynamics data from preclinical studies in Solid tumours (gynaecological cancers) presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)
- 26 Oct 2022 Adverse events and efficacy data from a phase I/II trial in Solid tumours (gynaecological cancers) presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)